The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | Results from a first-in-human study of a Type II JAK2 inhibitor (AJ1-11095) in myelofibrosis
John Mascarenhas, MD, Icahn School of Medicine at Mount Sinai, New York, NY, presents the initial findings from the Phase I first-in-human AJX-101 clinical trial (NCT06343805) investigating AJ1-11095 in patients with myelofibrosis (MF) previously treated with a Type I JAK2 inhibitor. Dr Mascarenhas notes that this agent, which binds to and stabilizes the inactive conformation of JAK2, has shown promising results, including deep spleen and symptom responses and reduction in disease allele burden. He also explains the rationale for exploring this therapeutic approach in MF, and looks forward to future trials in other patient populations. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
